IP Library Granted Patent US 12679832
Granted Patent B2
US 12679832 · App. 19/224,687 · Granted Jul 14, 2026

Compounds and their uses as CD38 inhibitors

Inventors: Jianbei Xi (Nanjing, CN); Guohuang Fan (Nanjing, CN); Jianfei Wang (Nanjing, CN); Kin Chiu Fong (Nanjing, CN)
Assignee: Nanjing Immunophage Biotech Co., Ltd.
C07D413/04A61K31/416A61K31/423A61K31/427A61K31/4439A61K31/4965A61K31/501A61K31/506A61K31/5377C07D277/28C07D401/04C07D401/14C07D405/14C07D417/04C07D417/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12679832
App. No.
19/224,687
Granted
Jul 14, 2026
Kind
B2
Abstract

The present invention provides compounds of Formula I which can be used as CD38 inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by CD38 by administering the compounds of the invention.

Claims (50)

1 . A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

A 1 is

wherein A 1 is optionally substituted with 0, 1 or 2 substituents independently selected from methyl and trifluoromethyl;

A 2 is

wherein A 2 is optionally substituted with 0 or 1 substituent selected from —CN, methyl, isopropyl, trifluoromethyl, methoxy, cyclobutoxy, oxetan-3-yloxy, —NH 2 , —NHCH 3 , and —N(CH 3 ) 2 ;

A 3 is

wherein A 3 is optionally substituted with 0, 1 or 2 substituents independently selected from —CN, —OCH 2 CH 2 OCH 3 , —COCH 3 , —F, —Cl, methyl, trifluoromethyl, hydroxyethoxy, carboxymethoxy, hydroxy, and methoxy; and

R is H or C 1-6 alkyl.

2 . The compound of claim 1 , wherein A 1 is unsubstituted.

3 . The compound of claim 1 , wherein A 2 is substituted with trifluoromethyl.

4 . The compound of claim 1 , wherein A 3 is

5 . The compound of claim 1 , wherein A 3 is

6 . The compound of claim 1 , wherein R is H.

7 . The compound of claim 1 , wherein R is C 1-6 alkyl.

8 . The compound of claim 2 , wherein A 2 is substituted with trifluoromethyl.

9 . The compound of claim 8 , wherein R is H.

10 . The compound of claim 8 , wherein R is methyl.

11 . The compound of claim 9 , wherein A 3 is

12 . The compound of claim 11 , wherein A 3 is substituted with a substituent selected from —CN, —OCH 2 CH 2 OCH 3 , —COCH 3 , —F, —Cl, methyl, trifluoromethyl, hydroxyethoxy, carboxymethoxy, hydroxy, and methoxy.

13 . The compound of claim 9 , wherein A 3 is

14 . The compound of claim 13 , wherein A 3 is unsubstituted with a substituent selected from —CN, —OCH 2 CH 2 OCH 3 , —COCH 3 , —F, —Cl, methyl, trifluoromethyl, hydroxyethoxy, carboxymethoxy, hydroxy, and methoxy.

15 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

16 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

17 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

18 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

19 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

20 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

21 . A pharmaceutical composition comprising:

a compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable or excipient.

22 . The pharmaceutical composition of claim 21 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

23 . The pharmaceutical composition of claim 21 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

24 . The pharmaceutical composition of claim 21 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

25 . The pharmaceutical composition of claim 21 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

26 . The pharmaceutical composition of claim 21 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

27 . The pharmaceutical composition of claim 21 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

28 . A method of inhibiting CD38 function in a cell, comprising contacting a compound of claim 1 or a pharmaceutically acceptable salt thereof with the cell.